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The objective of this study was to investigate screening performance measures in the English screening units that began inviting
women aged 65–70 between 1 April 2001 and 1 April 2004. We analysed results after each unit commenced inviting women aged
65–70. In addition, we analysed data from units that invited this age group for a second time between 1 April 2004 and 31 March
2007. Results for women aged 65–70 were compared to women aged 50–64 and 60–64. Average uptake was 72.8% for women
aged 65–70 and 76.7% for women aged 50–64. For women screened within the last 5 years, uptake was 88.7% for older women
and 89.1% for younger women. For women previously screened within 5 years the invasive cancer detection rate was 17% higher in
the 65–70 age group than in the 60–64 age group. The rates of recall to assessment and PPV were 3.5 and 27.6% in women aged
65–70 and 3.4 and 24.6% in women aged 50–64 respectively. These results suggest that, as in the earlier demonstration studies,
uptake rates remain high in older women, and many more older women attend following an invitation than had previously self-
referred. The cancer detection rate is higher in this older age group, whereas rates of recall are generally similar to those in younger
women; consequently the PPV is also higher in older women.
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When the UK NHS Breast Screening Programme (NHSBSP)
began in 1988, women aged between 50 and 64 years were invited
to three yearly screening, whereas older women were able to self-
refer. (Forrest, 1986). A survey in 1995 showed that in many
countries women aged up to 69 or 70 are invited to screening
(Shapiro et al, 1998). Although breast screening is acknowledged
as efficacious for women aged 50–69, when the UK programme
commenced there was concern regarding possible lower uptake
and reduced cost-effectiveness in older women (Moss et al, 2001).
More recently, results from three demonstration studies in
England, in which invitations were extended to women aged
65–69, suggested that older women who have previously been
routinely screened by the programme had similar uptake patterns
to younger women, and screening these women was estimated
to be as cost-effective as for the 50–64 age group (Moss et al,
2001). As a result of these studies, the expansion of the programme
to invite women up to the age of 70 was announced in the
NHS Cancer Plan in 2000 (Department of Health, 2000). The
publication also announced the introduction of two-view mam-
mography at the incident screen. English units were expected
to have begun this by 2003 and to have started including women
aged 65–70 into the routine invitation system by the end of
2004.
The aim of this study was to investigate if the implementation of
this policy change gave similar results to those from the
demonstration studies. We analysed results from those units that
began inviting the 65–70 age group between 1 April 2001 and 1
April 2004 and therefore had completed at least a full 3-year
screening round by 31 March 2007.
METHODS
Between April 2001 and April 2004, 36 units in England began
inviting women aged between 65 and 70, in addition to women
aged 50–64, to screening. These units were distributed throughout
England and represented approximately 40% of both the total
number of units and of the target population of the screening
programme.
Aggregated information on activity and outcomes is reported
annually by screening units on statutory KC62 returns, which
report on specific cohorts of women; for example data for 2002
relate to women screened between 1 April 2001 and 31 March 2002.
As the majority of women aged 65–70 will have been previously
screened, performance measures (rates of recall, cancer detection,
benign biopsy and non-operative diagnosis of cancer) were
calculated for women who had previously been screened by the
programme both within the last 5 years and more than 5 years
previously. Uptake of invitation was calculated for all women
according to previous screening history. Results for the 65–70 age
group were compared with those for both the previous target age
range (50–64) and the oldest age group in that range (60–64). The
statistical significance of these comparisons was tested using a
two-sample test of proportions in Stata version 9.2.
We examined data for each unit for the first 3 complete years
after they commenced inviting the 50–70 age group. For example,
in a unit beginning to invite the 65–70 age group in August 2003,
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swe used data for the period 1 April 2004 to 31 March 2007. To
estimate the increase in the number of older women being
screened due to the expansion of invitation to the 65–70 age
group, we compared the number of women aged 65–70 screened
in this 3-year period with the number of women who self-referred
in the 65–69 age group (because data for age 70 were not available
before 2003) in the 3 complete years prior to each unit inviting
older women.
During initial invitation of older women (round 1), those aged
between 65 and 67 will have been invited to screening 3 years
previously, and are likely to form the majority of women screened
within the last 5 years, whereas those aged 68–70 are likely not to
have been invited for 6 years and will form the majority of women
last screened more than 5 years previously. In addition, for the 23
units that began the expansion between April 2001 and April 2003,
we examined data as they began the re-invitation of the 65–70 age
group (round 2) to screening, when all women will have been
invited to screening within the last 3 years. Figure 1 shows the
previous screening history of women aged 65–70 at both rounds 1
and 2 assuming that before the policy change women had received
their last invitation between ages 62 and 64.9 years.
In 2004, an annex was added to the data return providing
anonymised individual-based pathology data for all screen-
detected cancers. The quality of these data was poor in the first
year, and we therefore used data from 2005 onwards. Data on all
cancers detected by the screening units during the 3-year period
between 1 April 2004 and 31 March 2007 (KC62 year, 2005–2007)
were used to calculate the Nottingham Prognostic Index (NPI) in
order to compare the prognosis for the 65–70 age group with that
of younger women. The index was derived from a series of women
with primary breast cancer and uses lymph node status, tumour
size and pathological grade. From this series three subsets of
patients were identified; those with a good prognosis, a moderate
prognosis and a poor prognosis (survival at 10 years after
diagnosis was 88, 60 and 18% respectively) (Blamey, 2002).
RESULTS
The dates when the 36 units began inviting women up to the age of
70 are shown in Figure 2. Units commencing between April 2001
and April 2003 began re-inviting the 65–70 age group between
April 2004 and April 2006. Although two units commenced
inviting the 65–70 age group in April 2001, the majority of the
units began in 2003. By this time approximately 60% of the units
had already started taking two views at the incident screen, and a
further third started at the same time; therefore most women
invited by the units would have had two mammographic views
taken.
A total of 516213 women aged 65–70 were invited to screening
in the first round, and 201589 in the second round. Uptake for this
age group was 72.8% at both rounds. Average uptake in the two
rounds was 76.7%, and 76.8% for the 50–64 and 60–64 age groups
respectively. The number of older women screened in the first
round was more than five times the number (67546, aged 65–69)
who self-referred in these units in the 3 years prior to them
beginning to invite older women.
Table 1 shows the uptake rates by age group, invitation type
and round. A percentage of women aged 65–70 were invited
for the first time. (Reasons for this may include women moving to
the UK, previously screened women moving to a new area
whose screening history was not forwarded from their old area
and women previously recorded as ineligible now being invited).
At the first round, the 65–70 age group demonstrated similar
patterns of uptake to women aged 60–64, except for those
women whose last screen was more than 5 years ago, whose
uptake was higher (66.6 vs 46.0%). The results may reflect the fact
that the older women in the 65–70 age group would not have
been invited for 6 years. A proportion of older women in this age
group will have been screened more recently as a result of self-
referral, and this may explain why more than half of the 65–70 age
group had been screened within the last 5 years. At the second
round, for women screened more than 5 years previously, the older
age group showed a similar pattern of uptake to the 60–64 age
group; all these women will have been non-attenders at their last
invitation.
The overall recall to assessment rate in the 65–70 age group was
3.4% for women screened within the last 5 years and was similar to
the 60–64 age group at both rounds (Table 2). For women
screened more than 5 years previously the rate was 5.2% in the
older age group. This was similar to rates in the younger age
groups at the first round but at the second round rates decreased
in both the 50–64 and 60–64 age groups but remained higher in
the 65–70 age group.
The average invasive cancer detection rate in the 65–70 age
group was 7.6 per 1000 in women screened within the last 5 years
and 12.0 per 1000 in women screened at a longer screening interval
(Table 2). Both were significantly (Po0.001) higher than rates in
the 60–64 age group (6.5 per 1000 women screened and 8.9 per
1000 women screened respectively).
The in situ cancer detection rate was similar in the 60–64 and
65–70 age groups; 1.6 per 1000 women screened versus 1.7 per
1000 women screened for women screened within 5 years and 2.2
per 1000 women screened versus 2.6 per 1000 women screened in
women screened more than 5 years ago (Table 2).
In women screened within the last 5 years the small (o15mm)
invasive cancer detection rate was significantly (Po0.001) higher
in the 65–70 age group than the 60–64 age group (4.4 per 1000
women screened vs 3.7 per 1000 women screened) (Table 2). Rates
were also higher in older women screened more than 5 years ago
but the rates decreased from the first to the second round in all age
groups (unlike in women screened within the last 5 years where
they remained stable).
The percentage of small (o15mm) invasive cancers was 55% in
the 50–64 age group, 57% in the 60–64 age group and 58% in the
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Figure 1 Age at invitation and previous screening history of older
women in units commencing invitation of 65–70 age group.
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s65–70 age group for women screened within the last 5 years. For
women screened more than 5 years previously the percentages
were 53, 52 and 51% respectively.
The positive predictive value of recall to assessment (PPV) was
significantly (Po0.001) higher in the 65–70 age group than the
60–64 age group for women screened both within the last 5 years
(27.6 vs 24.6%) and those with a longer screening interval (28.3 vs
21.8%).
Rates of benign surgical biopsies for the 65–70 age group were
0.06% in women screened within 5 years and 0.10% for women
screened more than 5 years previously. These were similar to those
in the 50–64 and 60–64 age groups. The overall percentages of
cancers with a non-operative diagnosis of cancer were also similar
between the 60–64 and 65–70 age groups with 95.1% of older
women screened within 5 years receiving a non-operative
diagnosis of cancer and 94.8% who were screened more than 5
year previously.
Table 3 shows the proportion of cancers (including those with
an unknown lymph node status) falling into each of the diagnostic
categories of the NPI. The proportion of cancers in older women
with a good prognosis was similar to that in the 60–64 age group.
DISCUSSION
Although units included in this study began including women aged
65–70 in the invitation system between April 2001 and April 2004,
most began inviting older women after December 2002; results
from the first invitation of the 65–70 age group therefore mainly
represented activity between 1 April 2003 and 31 March 2007,
whereas the results for the re-invitation of the 65–70 age group
were based on units that began earlier and represent activity
mainly between 1 April 2005 and 31 March 2007. The re-invitation
of the age group only represents a full 3-year screening round for 2
out of the 23 units. However, average performance measures in
England between April 2003 and March 2007 were stable apart
from recall rate which has decreased.
The results of this study showed that although uptake was lower
in women aged 65–70 than in women aged both 50–64 and 60–64
for all age groups, it was more than the 70% minimum target set by
the programme (NHS Breast Screening Programme, 2005). The
results are similar to those from the English demonstration studies
and results from screening programmes in both Denmark and the
Netherlands, which also invite women aged 65–69 and report
more than 70% of women accepting an invitation to screening
(Sarkeala et al, 2004).
The invasive cancer detection rate in women screened both
within 5 years and more than 5 years previously and the small
invasive cancer detection rate in women screened more than
5 years ago both decreased between the first and second rounds.
At the first round, in the 50–64 age group, these rates were higher
than the English average and thus results at the second round,
although based on fewer data, may better reflect rates as units
continue to invite women aged 65–70.
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Figure 2 Start date for programmes commencing to invite 65–70 age group between April 2001 and April 2004.
Table 1 Uptake of screening according to invitation type and screening
round
First round of
inviting 65–70
age group
Second round of
inviting 65–70
age group Overall
Invitation
type Invited
Uptake
(%) Invited
Uptake
(%) Invited
Uptake
(%)
First invitation
50–64 360432 74.0 130075 73.0 490507 73.7
60–64 7836 35.3 2713 36.8 10549 35.7
65–70 8209 31.7 2269 30.1 10478 31.4
Previously invited never screened
50–64 194771 21.0 77044 19.7 271815 20.6
60–64 50689 10.1 20590 9.6 71279 9.9
65–70 50349 8.5 18599 6.6 68948 8.0
Previous screen p5 years
50–64 1244889 89.3 471812 88.6 1716701 89.1
60–64 434364 89.8 175411 89.5 609775 89.7
65–70 288718 88.9 147893 88.3 436611 88.7
Previous screen 45 years
50–64 128460 51.5 50399 49.9 178859 51.1
60–64 61404 46.0 25054 44.9 86458 45.7
65–70 168937 66.6 32828 43.7 201765 62.8
Breast screening in women aged 65–70
RL Bennett et al
1045
British Journal of Cancer (2009) 100(7), 1043–1047 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sAs in the demonstration studies, the rise in breast cancer
incidence with age was reflected in the increased invasive cancer
detection rate in the 65–70 age group. However rates of both small
and overall invasive cancers in all age groups were higher in this
study than in the demonstration studies, probably as a result of
units now using two-view mammography at all incident screens.
However, a slower rate of tumour growth is suggested by an
increased mean sojourn time in the older age group (Tabar et al,
2000), this may suggest an increasing chance of overdiagnosis in
the older age group due to increasing all-cause mortality.
As a result of the increased invasive cancer detection rate in the
65–70 age group, and low rates of recall to assessment, the PPV
increased in older women. However, results from further units will
be watched with interest. The demonstration studies showed a
lower rate of recall in the older age group, although the
Netherlands, which has always invited the 50–70 age group, has
shown an increase in recall rate, as well as PPV and cancer
detection, with increasing age (National Evaluation Team for
Breast Cancer Screening, 2005).
In 2002, an IARC working group concluded, given the evidence
from randomised controlled trials, that breast screening pro-
grammes should target women aged 50–69 (IARC Working Group
on the Evaluation of Cancer-Preventive Strategies, 2002). Some
countries now routinely invite women aged over 70; women are
invited up to 74 years in Sweden and 75 years in the Netherlands.
In England, the recent publication of the Cancer Reform Strategy
announced the further expansion of the NHSBSP to women aged
47–73 years (Department of Health, 2007). The results from this
observational study of extending the upper age limit to 70 have
shown that although women above the age of invitation are able to
self-refer, the number doing so is far fewer than the number of
women in the same age group who attend following an invitation.
Consequently, current rates of self-referral in women aged 71–73
should not be used to predict future uptake in this age group. The
effect on resources of the further extension of the programme is
likely to be considerable if uptake for both the 71–73 and 47–49
age groups is similar to the 50–70 age group.
Calculation of the NPI
The index was calculated using the formula: size
(cm) 0.2þlymph node status (1–3)þgrade (Haybittle
et al, 1982). An index using a revised formula (size
(cm) 0.42þgrade 0.78) was calculated for cancers with un-
known lymph node status (The Breast Screening Frequency Trial
Group, 2002).
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